NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-CoV-2, nanoviricide drug which is in phase 1a/1b clinical trails for the treatment of Covid; and NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric cases. It also offers NV-CoV-2 Solution for injection, infusion, and inhalation to treat severe cases that are not yet hospitalized would be best performed by an injection; and injectable solution can be delivered directly into the lungs as a fog created using standard portable battery operated nebulizer devices which enables action at the most important site of infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia. In addition, the company provides Nanoviricide, a biomimetic platform technology designed to attack enveloped virus particles to deliver anti-viral payload into infected cells sparing uninfected cells to block replication cycle without toxicity. NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-05-15 |
2024-03 |
0 |
-0.16 |
N/A |
N/A |
2024-02-14 |
2023-12 |
0 |
-0.18 |
N/A |
N/A |
2023-11-14 |
2023-09 |
0 |
-0.17 |
N/A |
N/A |
2023-10-13 |
2023-06 |
0 |
-0.31 |
N/A |
N/A |
2023-05-15 |
2023-03 |
0 |
-0.15 |
N/A |
N/A |
2023-02-14 |
2022-12 |
0 |
-0.15 |
N/A |
N/A |
Date |
Firm |
Action |
From |
To |
2023-04-17 |
EF Hutton |
Upgrade |
|
Buy |
Date |
Name |
Relation |
Quantity |
Description |
2018-05-20 |
BONIUK MILTON |
Beneficial Owner of more than 10% of a Class of Security |
0.00 |
Conversion of Exercise of derivative security |
2022-08-07 |
DIWAN ANIL |
President |
470.96K |
Stock Gift |
2015-09-21 |
SEYMOUR EUGENEM.D. |
Chief Executive Officer |
1.25M |
Conversion of Exercise of derivative security |
2013-01-29 |
THERACOUR PHARMA INC |
Beneficial Owner of more than 10% of a Class of Security |
33.32M |
Sale |
2014-08-24 |
VYAS MEETA |
Chief Financial Officer |
147.02K |
Conversion of Exercise of derivative security |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Vanguard Group Inc |
458.42K |
527.18K |
3.90% |
2023-06-29 |
Blackrock Inc. |
160.95K |
185.09K |
1.37% |
2023-06-29 |
Compagnie Lombard Odier Scma |
150.00K |
172.50K |
1.28% |
2023-06-29 |
Geode Capital Management, LLC |
111.29K |
127.99K |
0.95% |
2023-06-29 |
Bridgeway Capital Management, Inc. |
94.04K |
108.14K |
0.80% |
2023-06-29 |
Renaissance Technologies, LLC |
78.60K |
90.39K |
0.67% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Vanguard Total Stock Market Index Fund |
300.19K |
345.22K |
2.56% |
2023-06-29 |
Vanguard Extended Market Index Fund |
154.51K |
177.69K |
1.32% |
2023-06-29 |
Bridgeway Funds Inc-Ultra Small Company Market Fund |
94.04K |
108.14K |
0.80% |
2023-05-30 |
Fidelity Extended Market Index Fund |
81.28K |
85.34K |
0.69% |
2023-05-30 |
Fidelity Series Total Market Index Fund |
15.31K |
16.08K |
0.13% |
2023-05-30 |
Fidelity Total Market Index Fund |
8.25K |
8.66K |
0.07% |
Split |
Date |
1 : 20 |
2019-09-24 |
0.28571 : 1 |
2013-09-10 |